Effect of ketoconazole on hepatic oxidative drug metabolism

Abstract

Several clinical reports have suggested (but not demonstrated) that ketoconazole, a broad-spectrum antifungal drug, may inhibit hepatic oxidative drug metabolism in man. Ketoconazole apparently inhibits caffeine and aminopyrine oxidation in the rat. The influence of ketoconazole on theophylline and chlordiazepoxide kinetics in man was studied. These studies were performed before and after varying doses of ketoconazole within the currently accepted therapeutic range. Ketoconazole had no effect on theophylline clearance, whereas the drug impaired chlordiazepoxide clearance from plasma. After a single dose of ketoconazole, there was a 20% decrease in clearance and a 26% decrease in volume of distribution without evidence of inhibition of drug metabolism. These changes apparently were not related to ketoconazole dose. After repetitive dosing with ketoconazole, chlordiazepoxide clearance decreased by 38% and was associated with reduced concentrations of its first oxidative metabolite, N-desmethylchlordiazepoxide. Ketoconazole inhibits at least 1 subset of the hepatic mixed-function oxidase system, but is not as general an inhibitor of hepatic oxidative drug metabolism as cimetidine appears to be. For some coadministered drugs ketoconazole may also have an effect on other kinetic parameters such as volume of distribution. Clinically important drug interactions may occur with the concurrent use of ketoconazole.